State-of-the-art evidence in the treatment of systemic sclerosis

JE Pope, CP Denton, SR Johnson… - Nature Reviews …, 2023 - nature.com
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Management of endothelial dysfunction in systemic sclerosis: current and developing strategies

DC Zanin-Silva, M Santana-Gonçalves… - Frontiers in …, 2021 - frontiersin.org
Systemic Sclerosis (SSc) is an autoimmune disease marked by dysregulation of the immune
system, tissue fibrosis and dysfunction of the vasculature. Vascular damage, remodeling and …

Raynaud's phenomenon

AL Herrick, FM Wigley - Best practice & research Clinical rheumatology, 2020 - Elsevier
Raynaud's phenomenon (RP) is common, affecting approximately 5% of the population, and
is important to the rheumatologist because it is often the presenting symptom of connective …

[HTML][HTML] Raynaud's phenomenon

A Haque, M Hughes - Clinical Medicine, 2020 - Elsevier
Raynaud's phenomenon (RP) is a common vasospastic condition which affects~ 5% of the
general population. The majority of individuals have primary RP; however, Raynaud's can …

Raynaud's phenomenon with focus on systemic sclerosis

M Maciejewska, M Sikora, C Maciejewski… - Journal of clinical …, 2022 - mdpi.com
Raynaud's phenomenon is a painful vascular condition in which abnormal vasoconstriction
of the digital arteries causes blanching of the skin. The treatment approach can vary …

Raynaud's phenomenon and related vasospastic disorders

E Choi, S Henkin - Vascular Medicine, 2021 - journals.sagepub.com
Raynaud's phenomenon, which is characterized by episodic digital pallor, cyanosis and
rubor upon exposure to cold environment or to stress, is relatively common, although the …

Part II: the treatment of primary and secondary Raynaud's phenomenon

P Curtiss, K Svigos, Z Schwager, KL Sicco… - Journal of the American …, 2024 - Elsevier
Raynaud phenomenon (RP) presents with either primary or secondary disease, and both
have the potential to negatively impact patient quality of life. First-line management of RP …

An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis

ZH McMahan, ER Volkmann - Expert opinion on pharmacotherapy, 2020 - Taylor & Francis
ABSTRACT Introduction Systemic sclerosis (SSc) is a multi-dimensional connective tissue
disease of unknown etiology. Given the immense clinical complexity of SSc, the treatment of …

Treatment of systemic sclerosis

B Thoreau, B Chaigne, A Renaud, L Mouthon - La Presse Médicale, 2021 - Elsevier
Systemic sclerosis (SSc) is a rare connective tissue disease characterized by skin and
visceral fibrosis, vascular hyperreactivity and obliterative vasculopathy. Some of its …

Raynaud's phenomenon and digital ulcers: advances in evaluation and management

AL Herrick - Current Opinion in Rheumatology, 2021 - journals.lww.com
Raynaud's phenomenon and digital ulcers: advances in evaluat... : Current Opinion in
Rheumatology Raynaud's phenomenon and digital ulcers: advances in evaluation and …